5. Lindner R. and Ungewickell E., J. Biol. Chem.,
267: 16567-73 (1992).
6. Robinson M. S. and Kries T. E., Cell, 69:
129-38 (1992).
7. Klumpermann J., et al., J. Cell Biol., 121:
997-1010
taurocholate in excystation of Cryptosporidium
parvum and infection of tissue culture. J.
Parasitol., 87(5), 997-1000 (2001).
10. Mrestani, Y., et al., The effect of a functional group
in penicillin derivatives
synthetic sphingomyelins using high-performance
thin-layer chromatography. Eur. J. Biochem.,
266(3), 997-1002 (1999).
4. Beckedorf, A. I., et al., Mapping and sequencing of
cardiolipins from Geobacillus
., Regulation of antioxidant metabolism
by translation initiation factor 2α. J. Cell Biol., 152,
997-1006 (2001).
3. Lu, J., et al., The interferon-induced double-
stranded RNA-activated protein kinase
., Characterization of a MAPKK-
like protein kinase TOPK. Biochem. Biophys. Res.
Commun., 325, 997-1004 (2004).
2. Simons-Evelyn, M. et al., PBK/TOPK is a novel
mitotic kinase which is upregulated
., Characterization of a MAPKK-
like protein kinase TOPK. Biochem. Biophys. Res.
Commun., 325, 997-1004 (2004).
2. Simons-Evelyn, M. et al., PBK/TOPK is a novel
mitotic kinase which is upregulated
Lot Number 051M0821:
997 nmole/min/mg
Procedure
Preparation Instructions
Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM
glycerol 2-phosphate, 20 mM MgCl2, 25 mM MnCl2,
5 mM EGTA, and 2 mM EDTA
., Characterization of a MAPKK-
like protein kinase TOPK. Biochem. Biophys. Res.
Commun., 325, 997-1004 (2004).
2. Simons-Evelyn, M. et al., PBK/TOPK is a novel
mitotic kinase which is upregulated
., Characterization of a MAPKK-
like protein kinase TOPK. Biochem. Biophys. Res.
Commun., 325, 997-1004 (2004).
2. Simons-Evelyn, M. et al., PBK/TOPK is a novel
mitotic kinase which is upregulated
., Characterization of a MAPKK-
like protein kinase TOPK. Biochem. Biophys. Res.
Commun., 325, 997-1004 (2004).
2. Simons-Evelyn, M. et al., PBK/TOPK is a novel
mitotic kinase which is upregulated
Standard by
mixing 3 L of the 100 mM Glutathione
Standard with 997 L of purified water.
2. Prepare a 3 µM GSH Standard by mixing
5 L of the 300 µM GSH Standard with
495 L of
Tetrahedron Lett., 43, 997.
18. C. Grandjean, et al. (2001) Chem. Eur. J., 7, 230.
19. C. Grandjean, et al. (2000) Angew. Chem., 112, 1110.
20. J. C. Spetzler & T. Hoeg-Jensen (1999) J. Pept. Sci., 5, 582.
21. O.
Tetrahedron Lett., 43, 997.
26. C. Grandjean, et al. (2001) Chem. Eur. J., 7, 230.
27. C. Grandjean, et al. (2000) Angew. Chem., 112, 1110.
28. J. C. Spetzler & T. Hoeg-Jensen (1999) J. Pept. Sci., 5, 582.
29. O.
4. Samuelsson, B., et al., Thromboxanes
and thromboxanes. Annu. Rev.
Biochem., 47, 997-1029 (1978).
5. Long, C. R., et al., Thromboxane B2
induced changes in renal blood flow,
renal interstitial
1998) Death by a thousand cuts: an ever
increasing list of caspase substrates. Cell Death Differ. 5(12), 997-1000.
Homogeneous Caspases Assay, fluorimetric y Version 09
http://www.sigmaaldrich.com
duplicate wells.
1. Make a 3000 ng/ml stock solution by diluting 3 µl of the 1 mg/ml standard into 997 µl of 1X
ELISA Diluent. Then make a 92.3 ng/ml working stock solution by diluting 30.8 µl
4. Samuelsson, B., et al., Prostaglandins and
thromboxanes. Annu Rev Biochem; 47, 997-1029
(1978).
5. Long, C. R., et al., Prostaglandin E2 induced
changes in renal blood flow, renal interstitial
DNA
damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol.
2002;4:993-997. PMID: 12447390
12. Crowe SL, Movsesyan VA, Jorgensen TJ, Kondratyev A. Rapid phosphorylation of
sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J
Exp Med 188:997-1001 (1998)
Kong YY, Feiger, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli, Elliot R,
McCabe
Fluid Aß40 and Aß42: Natural Course and Clinical
Usefulness, Frontiers in Bioscience 7: 997-1006 (2002).
5. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K.,
Eikenberg O.
Fluid Aß40 and Aß42: Natural Course and Clinical
Usefulness, Frontiers in Bioscience 7: 997-1006 (2002).
5. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K.,
Eikenberg O.
sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J
Exp Med 188:997-1001 (1998)
Hofbauer, LC and Schoppet M. Clinical implications of the
osteoprotegerin/RANKL